References
- Bobek LA, Levine MJ. Cystatins – inhibitors of cysteine proteinases. Crit. Rev. Oral. Biol. Med.3, 307–332 (1992).
- Vinters HV, Nishimura GS, Secor DL, Pardridge WM. Immunoreactive A4 and γ-trace peptide colocalization in amyloidotic arteriolar lesions in brains of patients with Alzheimer’s disease. Am. J. Pathol.137, 233–240 (1990).
- Maruyama K, Ikeda S, Ishihara T, Allsop D, Yanagisawa N. Immunohistochemical characterization of cerebrovascular amyloid in 46 autopsied cases using antibodies to β protein and cystatin C. Stroke21, 397–403 (1990).
- Itoh Y, Yamada M, Hayakawa M, Otomo E, Miyatake T. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J. Neurol. Sci.116, 135–141 (1993).
- Haan J, Maat-Schieman MLC, van Duinen SG, Jensson O, Thorsteinsson L, Roos RAC. Co-localization of β/A4 and cystatin C in cortical blood vessels in Dutch, but not in Icelandic hereditary cerebral hemorrhage with amyloidosis. Acta Neurol. Scand.89, 367–371 (1994).
- Levy E, Sastre M, Kumar A et al. Codeposition of cystatin C with amyloid-β protein in the brain of Alzheimer’s disease patients. J. Neuropathol. Exp. Neurol.60, 94–104 (2001).
- Wei L, Walker LC, Levy E. Cystatin C: Icelandic-like mutation in an animal model of cerebrovascular β amyloidosis. Stroke27, 2080–2085 (1996).
- Uchida K, Kuroki K, Yoshino T, Yamaguchi R, Tateyama S. Immunohistochemical study of constituents other than β-protein in canine senile plaques and cerebral amyloid angiopathy. Acta Neuropathol. (Berl.)93, 277–284 (1997).
- Steinhoff T, Moritz E, Wollmer MA, Mohajeri MH, Kins S, Nitsch RM. Increased cystatin C in astrocytes of transgenic mice expressing the K670N–M671L mutation of the amyloid precursor protein and deposition in brain amyloid plaques. Neurobiol. Dis.8, 647–654 (2001).
- Sastre M, Calero M, Pawlik M et al. Binding of cystatin C to Alzheimer’s amyloid β inhibits amyloid fibril formation. Neurobiol. Aging25, 1033–1043 (2004).
- Pawlik M, Sastre M, Calero M et al. Overexpression of human cystatin C in transgenic mice does not affect levels of endogenous brain amyloid β peptide. J. Mol. Neurosci.22, 13–18 (2004).
- Bai Y, Markham K, Chen F et al. The in vivo brain interactome of the amyloid precursor protein. Mol. Cell. Proteomics7, 15–34 (2008).
- Selenica ML, Wang X, Ostergaard-Pedersen L, Westlind-Danielsson A, Grubb A. Cystatin C reduces the in vitro formation of soluble Aβ1-42 oligomers and protofibrils. Scand. J. Clin. LAβ. Invest.67, 179–190 (2007).
- Mi W, Pawlik M, Sastre M et al. Cystatin C inhibits amyloid-β deposition in Alzheimer’s disease mouse models. Nat. Genet.39, 1440–1442 (2007).
- Kaeser SA, Herzig MC, Coomaraswamy J et al. Cystatin C modulates cerebral β-amyloidosis. Nat. Genet.39, 1437–1439 (2007).
- Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Curr. Opin. Nephrol. Hypertens.15, 610–616 (2006).
- Levy E, Jaskolski M, Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol.16, 60–70 (2006).
- Ghidoni R, Benussi L, Paterlini A et al. Presenilin 2 mutations alter cystatin C trafficking in mouse primary neurons. Neurobiol. Aging28, 371–376 (2006).
- Finckh U, von Der Kammer H, Velden J et al. Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch. Neurol.57, 1579–1583 (2000).
- Benussi L, Ghidoni R, Steinhoff T et al. Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol. Dis.13, 15–21 (2003).
- Paraoan L, Ratnayaka A, Spiller DG, Hiscott P, White MR, Grierson I. Unexpected intracellular localization of the AMD-associated cystatin C variant. Traffic5, 884–895 (2004).
Website
- Gene overview of all published AD association studies for CST3. www.alzforum.org/res/com/gen/alzgene/geneoverview.asp?geneid=66